+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Darunavir"

HIV Clinical Trials Market - Global Forecast 2025-2032 - Product Thumbnail Image

HIV Clinical Trials Market - Global Forecast 2025-2032

  • Report
  • October 2025
  • 184 Pages
  • Global
From
From
HIV Antivirals Market - Global Forecast 2025-2030 - Product Thumbnail Image

HIV Antivirals Market - Global Forecast 2025-2030

  • Report
  • August 2025
  • 192 Pages
  • Global
From
HIV Drugs Market Report 2025 - Product Thumbnail Image

HIV Drugs Market Report 2025

  • Report
  • September 2025
  • 250 Pages
  • Global
From
  • 4 Results (Page 1 of 1)
Loading Indicator

Darunavir is a protease inhibitor used to treat immune disorders, such as HIV and AIDS. It is used in combination with other antiretroviral drugs to reduce the amount of HIV in the body and to prevent the virus from replicating. Darunavir is also used to treat hepatitis C virus (HCV) infection. It works by blocking the action of the HCV protease enzyme, which is necessary for the virus to replicate. Darunavir is available in tablet and oral suspension forms. Darunavir is a widely used drug in the treatment of immune disorders. It is generally well tolerated and has few side effects. It is also effective in reducing the risk of HIV transmission. Darunavir is available in generic form, as well as under the brand name Prezista. The Darunavir market is highly competitive, with many companies offering generic and branded versions of the drug. Some of the major players in the market include AbbVie, Bristol-Myers Squibb, Gilead Sciences, Merck, and Pfizer. Show Less Read more